Document is current
Any future updates will be listed below
-
Authors
Komiya, Shiro
Katsumata, Mari
Ozawa, Moe
Haze, Tatsuya
Kawano, Rina
Ohki, Yuki
Suzuki, Shota
Kobayashi, Yusuke
Fujiwara, Akira
Saka, Sanae
Tamura, Kouichi
Hirawa, Nobuhito https://orcid.org/0000-0001-5824-3652
-
Clinical Trials BETA
Clinical trials referenced in this document:
umin000014763 at UMIN JapanDocuments that mention this clinical trial
Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial
https://doi.org/10.1007/s10157-022-02224-x
-
Funding
Funding for this research was provided by:
Graduate Center
- License Information
-
More Information
Article History
Received: 20 January 2022
Accepted: 4 April 2022
First Online: 26 April 2022
Declarations
:
: Honoraria: Koichi Tamura (Takeda, AstraZeneca, Daiichi-Sankyo, Novartis), Nobuhito Hirawa (Takeda), Grants received: Koichi Tamura (Bayer, Takeda, Daiichi-Sankyo, AstraZeneca, Ono Pharmaceutical, Kyowa Kirin, Novartis).
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB approval number D1405025) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
